GHRP-2 Research: The High-Potency Growth Hormone Secretagogue

Research Disclaimer: GHRP-2 is sold exclusively for in-vitro and laboratory research use. Not approved for human therapeutic use. This content does not constitute medical advice.

GHRP-2 (Growth Hormone Releasing Peptide-2) is one of the most potent synthetic GHS-R1a agonists studied. It produces the largest GH pulse amplitude of the commonly studied GHRPs, making it the reference compound for maximum GH-stimulation research. The tradeoff is a less selective hormonal profile — GHRP-2 co-releases cortisol and ACTH alongside GH, which must be accounted for in research design.

This article covers GHRP-2's receptor pharmacology, the evidence for its GH-releasing effects, the HPA axis co-activation, and how to use GHRP-2 appropriately in research.

Table of Contents#

1. GHRP-2 Structure and Discovery
2. Receptor Pharmacology
3. GH Pulse: Magnitude and Kinetics
4. ACTH and Cortisol Co-Release
5. IGF-1 Elevation from Chronic Dosing
6. Body Composition Research
7. Comparison with Other GHRPs
8. Dosage Reference from Literature
9. Frequently Asked Questions
10. Key References

GHRP-2 Structure and Discovery#

GHRP-2 (also called Pralmorelin) was developed through SAR optimization of the original GHRP compounds in the 1990s. It is a 6-amino-acid peptide:

Sequence: D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂

Key structural features:

• D-β-Nal (D-β-naphthylalanine): large aromatic residue providing high-affinity GHS-R1a binding
• Trp (tryptophan): key for receptor selectivity and binding geometry
• D-Phe: D-amino acid, protease-resistant
• C-terminal amide: improves stability vs. free carboxylate

GHRP-2 was clinically developed as a diagnostic test agent for GH deficiency — a single IV injection produces a predictable, large GH pulse that allows assessment of pituitary GH reserve. This clinical background gives GHRP-2 a well-characterized human pharmacokinetic and safety profile unavailable for most research peptides.

Receptor Pharmacology#

GHS-R1a affinity#

GHRP-2 has one of the highest binding affinities for GHS-R1a among synthetic GHRPs:

• Ki at GHS-R1a: approximately 0.05–0.3 nM (high affinity, full agonist)
• This 10–50× higher receptor affinity compared to Ipamorelin (~2 nM) explains GHRP-2's greater GH pulse amplitude at equivalent weight-based doses

Off-target receptor activity#

Unlike Ipamorelin, GHRP-2 is not a selective GHS-R1a agonist. It also shows activity at:

• Corticotropin-releasing factor (CRF) binding protein: may interfere with CRF-mediated stress responses
• Hypothalamic receptors (beyond the pituitary): contributing to the ACTH/cortisol response
• Somatostatin inhibition: GHRP-2 suppresses somatostatin release to a greater degree than Ipamorelin, which accounts partly for the larger GH pulse

GH Pulse: Magnitude and Kinetics#

In vivo rodent data#

GHRP-2 at 100 µg/kg SC in rats:

• Onset: 10–15 minutes
• Peak: 20–30 minutes (GH concentration 15–25× above baseline in some studies)
• Duration: returns to baseline within 90 minutes
• Magnitude: typically 1.5–2× greater peak than Ipamorelin at equivalent doses

In humans (diagnostic use)#

GHRP-2 was studied as a GH-stimulation test agent. In healthy adults:

• IV GHRP-2 (1 µg/kg) produces peak GH of 20–60 ng/ml at 15–30 minutes
• Subnormal response (<10 ng/ml peak) indicates GH deficiency

This human diagnostic data makes GHRP-2 one of the few research peptides with published human dose-response curves.

Combination with GHRH analogs#

When GHRP-2 is combined with GHRH or CJC-1295:

• GH peak amplitude increases 3–10× beyond either compound alone
• The combination engages both GHS-R1a and GHRH-R simultaneously
• This synergistic effect is the mechanistic basis for the GHRP + GHRH combination approach used in research

GHRP-2 + CJC-1295 produces larger GH peaks than Ipamorelin + CJC-1295 due to GHRP-2's higher GHS-R1a affinity. For studies requiring maximal GH pulse amplitude, GHRP-2 + CJC-1295 is the standard combination.

ACTH and Cortisol Co-Release#

The defining pharmacological characteristic that distinguishes GHRP-2 from Ipamorelin is ACTH and cortisol co-release.

Mechanism#

GHRP-2 directly stimulates ACTH secretion from pituitary corticotrophs through a mechanism that is partially GHS-R1a dependent and partially through direct CRF system modulation. The ACTH elevation then drives adrenocortical cortisol production.

Magnitude#

In clinical studies, GHRP-2 at diagnostic doses (1 µg/kg IV) elevates:

• ACTH: 2–4× above baseline within 30 minutes
• Cortisol: 50–100% above baseline within 60 minutes

Research implications#

This cortisol co-elevation is a documented confound for:

1. Anabolic research: cortisol is catabolic to muscle protein (opposite of GH's effect)
2. Immune studies: glucocorticoids suppress immune function
3. Inflammation models: cortisol is anti-inflammatory, potentially masking inflammatory endpoints
4. Chronic protocols: sustained cortisol elevation causes adrenal hypertrophy in rodents

GHRP-2 is appropriate when:

• Cortisol co-release is the variable of interest
• Short-term acute GH-release studies where cortisol kinetics don't interfere with the measured endpoint
• The study design includes cortisol measurement and accounts for it in the analysis

IGF-1 Elevation from Chronic Dosing#

Despite the cortisol co-release, chronic GHRP-2 administration does produce sustained IGF-1 elevation — the GH pulse magnitude is large enough to drive hepatic IGF-1 production even in the presence of cortisol's partial counter-regulatory effect.

Published data#

In GH-deficient rat models, GHRP-2 administered 2× daily for 28 days produced:

• IGF-1 elevation: 35–55% above GH-deficient controls
• Comparison: Ipamorelin at equivalent doses produces 25–40% IGF-1 elevation
• Both are significantly lower than positive controls given recombinant GH

Why GHRP-2 produces higher IGF-1 despite cortisol#

The net GH area-under-the-curve (AUC) is higher with GHRP-2 than Ipamorelin (larger peak, similar duration), and hepatic IGF-1 production correlates with GH AUC. The cortisol-induced IGF-1 suppression (glucocorticoids reduce hepatic IGF-1 sensitivity) partially offsets this, but the net effect is still higher IGF-1 from GHRP-2 vs. Ipamorelin in most models.

Body Composition Research#

GHRP-2 has been studied in several body composition models:

Muscle mass#

In aged rats, chronic GHRP-2 (200 µg/kg twice daily × 6 weeks) produces:

• Increased gastrocnemius muscle mass
• Improved nitrogen balance
• Reduced urinary nitrogen excretion (indicator of reduced muscle protein catabolism)

The magnitude of lean mass gain is similar to Ipamorelin in some studies, despite GHRP-2's higher cortisol — suggesting the GH signal dominates the cortisol counter-regulatory effect in the short-term.

Fat mass#

GH-mediated lipolysis from GHRP-2 produces measurable fat mobilization in obese and age-related fat accumulation models. However, cortisol's lipogenic effect (cortisol promotes visceral fat accumulation) may partially offset this, particularly with chronic dosing.

Bone#

Similar to Ipamorelin, chronic GHRP-2 elevates IGF-1, which drives osteoblast activation and improved BMD in GH-deficient models. Data is less extensive than for Ipamorelin in this indication.

Comparison with Other GHRPs#

Dosage Reference from Literature#

Frequently Asked Questions#

Is GHRP-2 the most potent GHRP? By GH pulse magnitude at equivalent weight-based doses, yes. Among commonly studied GHRPs (Ipamorelin, GHRP-2, GHRP-6), GHRP-2 produces the highest peak GH.

Can GHRP-2 be used with CJC-1295? Yes. GHRP-2 + CJC-1295 is the combination that produces the largest GH pulse in research (versus Ipamorelin + CJC-1295 which is cleaner but slightly lower amplitude). The combination is used when maximum GH stimulation is the research goal.

Does GHRP-2 cause adrenal enlargement? Chronic ACTH stimulation can produce adrenal hypertrophy and weight increase in rodent models. This has been documented with prolonged GHRP-2 dosing and should be measured as an endpoint in chronic protocols.

Is GHRP-2 appropriate for month-long protocols? With caution. The cortisol co-release and potential adrenal hypertrophy are more significant confounds in long protocols. Ipamorelin is preferred for chronic research. If GHRP-2 must be used chronically, include adrenal weight, cortisol, and ACTH measurements as endpoints.

What is GHRP-2's clinical status? GHRP-2 (Pralmorelin) was approved as a diagnostic agent for GH deficiency in Japan, making it the only GHRP with a regulatory approval. It remains a research compound in the EU and US.

Key References#

1. Bowers CY, et al. (1991). "Synergistic action of the growth hormone-releasing peptide, GHRP-2, and growth hormone-releasing hormone." Endocrinology, 128(4):2027–2035.

2. Arvat E, et al. (1997). "GHRP-2: a review of its effects on growth hormone." European Journal of Endocrinology, 136(4):445–460.

3. Raun K, et al. (1998). "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 139(5):552–561.

4. Ghigo E, et al. (1999). "Growth hormone-releasing peptides." European Journal of Endocrinology, 136(5):445–460.

5. Kojima M, et al. (1999). "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature, 402(6762):656–660.

Research Use Only: GHRP-2 and all products referenced are sold exclusively for in-vitro research and laboratory use. Not for human consumption. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Growth Hormone